173 related articles for article (PubMed ID: 36828080)
1. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
[TBL] [Abstract][Full Text] [Related]
2. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
[TBL] [Abstract][Full Text] [Related]
3. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.
Kim EH; Bird JA; Keet CA; Virkud YV; Herlihy L; Ye P; Smeekens JM; Guo R; Yue X; Penumarti A; Qaqish B; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2024 Jan; 153(1):173-181.e10. PubMed ID: 37815782
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
[TBL] [Abstract][Full Text] [Related]
6. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
[TBL] [Abstract][Full Text] [Related]
7. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.
Kim EH; Bird JA; Kulis M; Laubach S; Pons L; Shreffler W; Steele P; Kamilaris J; Vickery B; Burks AW
J Allergy Clin Immunol; 2011 Mar; 127(3):640-6.e1. PubMed ID: 21281959
[TBL] [Abstract][Full Text] [Related]
9. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.
Burk CM; Kulis M; Leung N; Kim EH; Burks AW; Vickery BP
Clin Exp Allergy; 2016 Feb; 46(2):347-53. PubMed ID: 26362760
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
Fleischer DM; Burks AW; Vickery BP; Scurlock AM; Wood RA; Jones SM; Sicherer SH; Liu AH; Stablein D; Henning AK; Mayer L; Lindblad R; Plaut M; Sampson HA;
J Allergy Clin Immunol; 2013 Jan; 131(1):119-27.e1-7. PubMed ID: 23265698
[TBL] [Abstract][Full Text] [Related]
12. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
13. Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study).
Davis CM; Anagnostou A; Devaraj S; Vita DT; Rivera F; Pitts K; Hearrell M; Minard C; Guffey D; Gupta M; Watkin L; Orange JS; Anvari S
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):566-576.e6. PubMed ID: 34890827
[TBL] [Abstract][Full Text] [Related]
14. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
15. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
[TBL] [Abstract][Full Text] [Related]
16. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
17. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
Nozawa A; Okamoto Y; Movérare R; Borres MP; Kurihara K
Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293
[TBL] [Abstract][Full Text] [Related]
18. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
[TBL] [Abstract][Full Text] [Related]
20. The clinical and immunological effects of Pru p 3 sublingual immunotherapy on peach and peanut allergy in patients with systemic reactions.
Gomez F; Bogas G; Gonzalez M; Campo P; Salas M; Diaz-Perales A; Rodriguez MJ; Prieto A; Barber D; Blanca M; Torres MJ; Mayorga C
Clin Exp Allergy; 2017 Mar; 47(3):339-350. PubMed ID: 28160513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
